Home > Urology > EAU 2019 > Prostate Cancer > When to Use Imaging and Imaging-guided Therapies

When to Use Imaging and Imaging-guided Therapies

Presented By
Dr Lorenzo Bianchi, Dr Carlo Andrea Bravi
Conference
EAU 2019

A clinical tool to guide physicians before suggesting 68Ga-PSMA PET/CT.

Which patient with biochemical recurrence after primary treatment for prostate cancer would result in a positive 68 Ga-PSMA PET/CT? The 2019 EAU Guideline panel recommends performing 68 Ga-PSMA PET/CT if the PSA level is >0.2 ng/mL, providing the results will influence treatment decisions, but it is unclear if this is cost-effective. Dr Lorenzo Bianchi (University of Bologna, Italy) built a prediction model to assess the risk of individual patients to have a positive PET/CT. Prostate cancer patients (n=703) with confirmed biochemical recurrence were stratified according to different clinical settings of recurrence: first PSA relapse (detection rate 40%), biochemical relapse after salvage therapy (detection rate 54%), PSA persistence after primary therapy (detection rate 60%), and disease progression before starting systemic therapies (detection rate ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on